Plain-English translation of NCT06640257 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new injectable medication called SHR-1314 to see if it can help adults with psoriatic arthritis—a condition that causes joint pain, swelling, and skin rashes. Half of the participants will receive the new medication, and half will receive a placebo (a fake injection) so researchers can fairly compare how well the treatment works. This is a Phase III trial, which means the medication has already shown promise in earlier studies.
Psoriatic arthritis can be difficult to treat, and many patients don't get enough relief from current medications. Researchers are testing this new medication to see if it offers better control of joint pain and skin symptoms for people who haven't responded well enough to existing treatments.
You likely qualify if…
You likely don't qualify if…
You will be screened over 4 weeks to confirm you qualify, then randomly assigned to either the new medication or placebo. The main treatment phase lasts 24 weeks, followed by a 24-week maintenance phase where you'll continue receiving your assigned treatment. After that, you'll have an 8-week safety follow-up period. During this time, you'll visit the clinic multiple times for injections and check-ups to see how well the treatment works and monitor for any side effects.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Enrollment target
~200 participants
Started
November 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Su Zhang, M.M
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.